Company intelligence / Profile preview
Shilpa Medicare
Raichur, Karnataka, Indiavbshilpa.com ↗
- Ownership
- Private
- Employees
- ~931
- Development stage
- Commercial
01
Overview
Shilpa Medicare has a strong commercial presence in generic APIs and formulations with multiple US FDA approvals. Its biosimilar division has launched adalimumab biosimilar and advanced several others to late-stage development. The company’s products are approved in the US, EU, India and other regulated markets.
- Therapeutic areas
- OncologyDermatologyRheumatologyGastroenterologyOphthalmologyNephrology
- Modalities
- Small moleculeRecombinant proteinMonoclonal antibody (including biosimilars)Peptides
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Dr. Reddy’s Laboratories Limited – production of Sputnik V vaccineICE S.r.l./PCA S.p.a. joint venture in ItalyLOBA Finchemie AG acquisition/MoU
Beyond the preview
Go deeper on Shilpa Medicare.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shilpa Medicare.